San Diego, CA. DTx Pharma announced today that it has received two grants from the National Institutes of Health (NIH) to support the development of its proprietary platform technology for enabling the activity of RNA medicines beyond the liver. Both grants are Phase 1 Small Business Innovation Grants (SBIR) awarded by the National Center for Advancing Translational Sciences (NCATS). The first grant of $321,555, entitled “systemic characterization of novel lipidated siRNA conjugates”, aims to explore the technology for diseases of the muscle and heart. The second grant of $301,212, entitled “development of conjugated oligonucleotide therapeutics for neuronal disease”, seeks to explore the potential of the technology for neurodegenerative diseases of the eye and CNS.
“The NIH understands the challenge of safely and effectively delivering RNA medicines beyond the liver. This new funding, along with the external validation of our approach leveraging fatty acids as targeting ligands to enable RNA medicines for ocular, CNS and systemic disease associated with it, has DTx well positioned to continue to advance the technology toward clinical development,” said Arthur Suckow, Ph.D., CEO of DTx Pharma.